Small molecule JAK inhibitors have emerged as a major therapeutic advancement in
treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that …

Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal
transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon …

The Janus tyrosine kinase (JAK) family of non-receptor tyrosine kinases includes four
isoforms (JAK1, JAK2, JAK3, and TYK2) and is responsible for signal transduction …

As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an
important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL …

JAK inhibitors impact multiple cytokine pathways simultaneously, enabling high efficacy in
treating complex diseases such as cancers and immune-mediated disorders. However, their …

In this review, we describe the current knowledge of the biology of the JAKs. The JAK family
comprises the four nonreceptor tyrosine kinases JAK1, JAK2, JAK3, and Tyk2, all key …

TYK2 is a key mediator of IL12, IL23, and type I interferon signaling, and these cytokines
have been implicated in the pathogenesis of multiple inflammatory and autoimmune …

Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-
inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and …

The action of Janus kinases (JAKs) is required for multiple cytokine signaling pathways, and
as such, JAK inhibitors hold promise for treatment of autoimmune disorders, including …

There is a critical need for safer and more convenient treatments for organ transplant
rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases …